In a study conducted in metastatic melanoma patients, patients who responded to pembrolizumab (anti-PD-1 therapy) showed proliferation of inter-tumoral CD8+ T-cells that directly correlated with tumor regression (Tumeh et al., 2014). This evidence concerns the gene CD8A and neoplasm.